Bone marrow drug is tested
A trial funded by the charity Yorkshire Cancer Research will examine if the drug Lenalidomide reduces the risk of life-threatening infections after transplants in patients with multiple myeloma.
Infection remained the main cause of death in the first 100 days after a transplant.
Advertisement
Hide AdAdvertisement
Hide AdBut laboratory tests by experts at St James's Hospital in Leeds on blood samples from patients around the country will examine if the treatment helps the immune system recover, a factor that could have a significant impact on survival rates.